Psychiatry · Los Angeles, CA
NPI
1578516811
Since 2006
Specialty
Psychiatry
Code 2084P0800X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
1891 Effie St
Los Angeles, CA, 90026
Phone (323) 644-2000
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$560K
2,581 prescriptions
Company payments, 2025
$108
From 2 companies
Medicare prescription drug claims, 2024
In 2024, the drug Mark Herbst prescribed most often to Medicare patients was Alprazolam, with 140 prescriptions and refills. In total Mark Herbst wrote 2,581 Medicare prescriptions that cost $560K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-12-06.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Alprazolam Generic | 140 | 178 | 33 | $1,295 |
| Lorazepam Generic | 93 | 101 | 22 | $919 |
| Diazepam Generic | 93 | 101 | 16 | $639 |
| Bupropion Xl Bupropion Hcl | 85 | 220 | 22 | $2,351 |
| Ozempic Semaglutide | 80 | 95 | 14 | $88K |
| Mirtazapine Generic | 77 | 163 | 21 | $1,751 |
| Doxepin Hcl Generic | 75 | 163 | 20 | $9,024 |
| Clonazepam Generic | 73 | 95 | 14 | $456 |
| Trazodone Hcl Generic | 66 | 108 | 16 | $1,931 |
| Zolpidem Tartrate Generic | 61 | 68 | 15 | $312 |
| Dayvigo Lemborexant | 59 | 59 | 13 | $22K |
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | 57 | 67 | 14 | $2,040 |
| Gabapentin Generic | 56 | 111 | 14 | $1,657 |
| Lamotrigine Generic | 45 | 105 | Under 11 | $793 |
| Duloxetine Hcl Generic | 40 | 118 | Under 11 | $1,276 |
Brand drugs: 433 claims; generic drugs: 2,135 claims; opioid claims: 51.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark Herbst $108 ($108 in general payments such as food, travel and fees) from 2 companies. The largest payer was Harmony Biosciences LLC with $79.19.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.